Skip to main content
. Author manuscript; available in PMC: 2024 Aug 15.
Published in final edited form as: J Antimicrob Chemother. 2018 Sep 1;73(9):2468–2474. doi: 10.1093/jac/dky221

Table 2.

Frequency of PDR

Variable Overall Urban sites Rural sites
Total specimens eligible for genotyping, n 379 249 130
Total successfully genotyped, n 321 205 116
Genotyping rate, % 85 82 89
HIVDR in all initiators, n 321 205 116
 any DRM, % (95% CI) 10.4 (5.4–19.1) 14.2 (6.6–27.9) 4.3 (1.2–14.3)
 PI DRMs, % (95% CI) 0.3 (0.1–1.5) 0.5 (0.1–2.6) 0
 NRTI DRMs, % (95% CI) 2.4 (0.4–12.9) 3.9 (0.6–20.9) 0
 NNRTI DRMs, % (95% CI) 10.0 (5.1–18.8) 13.7 (6.2–27.5) 4.3 (1.2–14.3)
HIVDR in initiators with no prior exposure to ARVs 223 141 82
 any DRM, % (95% CI) 10.4 (4.7–21.5) 13.5 (5.1–31.5) 5.3 (1.4–17.5)
 PI DRMs, % (95% CI) 0.3 (0.0–2.1) 0.5 (0.1–3.7) 0
 NRTI DRMs, % (95% CI) 2.8 (0.4–16.3) 4.6 (0.7–26.2) 0
 NNRTI DRMs, % (95% CI) 10.1 (4.4–21.3) 13.1 (4.7–31.2) 5.3 (1.4–17.5)
HIVDR in initiators with prior exposure to ARVs, n 29 23 6
 any DRM 14.7 (4.6–38.2) 18.8 (5.5–48.0) 0
 PI DRMs 1.1 (0.1–8.8)
 NRTI DRMs 1.6 (0.2–9.9)
 NNRTI DRMs 13.6 (3.9–37.9)

—, not displayed.

Data are presented as n, % or study design-weighted proportion [% (95% CI)].